Rhythm Pharmaceuticals Inc (RYTM)
59.77
-0.30
(-0.50%)
USD |
NASDAQ |
Nov 14, 16:00
59.74
-0.03
(-0.05%)
After-Hours: 20:00
Rhythm Pharmaceuticals Research and Development Expense (Quarterly): 37.93M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 37.93M |
| June 30, 2024 | 30.19M |
| March 31, 2024 | 128.66M |
| December 31, 2023 | 29.89M |
| September 30, 2023 | 33.57M |
| June 30, 2023 | 33.54M |
| March 31, 2023 | 37.94M |
| December 31, 2022 | 23.55M |
| September 30, 2022 | 21.12M |
| June 30, 2022 | 31.46M |
| March 31, 2022 | 32.51M |
| December 31, 2021 | 31.57M |
| September 30, 2021 | 27.54M |
| June 30, 2021 | 25.10M |
| March 31, 2021 | 19.91M |
| December 31, 2020 | 21.95M |
| September 30, 2020 | 23.00M |
| Date | Value |
|---|---|
| June 30, 2020 | 23.00M |
| March 31, 2020 | 22.50M |
| December 31, 2019 | 24.81M |
| September 30, 2019 | 26.57M |
| June 30, 2019 | 35.31M |
| March 31, 2019 | 22.76M |
| December 31, 2018 | 18.76M |
| September 30, 2018 | 10.70M |
| June 30, 2018 | 8.584M |
| March 31, 2018 | 12.29M |
| December 31, 2017 | 6.653M |
| September 30, 2017 | 5.971M |
| June 30, 2017 | 5.397M |
| March 31, 2017 | 4.873M |
| December 31, 2016 | 5.631M |
| September 30, 2016 | 5.419M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
19.91M
Minimum
Mar 2021
128.66M
Maximum
Mar 2024
32.99M
Average
28.72M
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.734B |
| TG Therapeutics Inc | 20.14M |
| Regeneron Pharmaceuticals Inc | 1.272B |
| Voyager Therapeutics Inc | 34.45M |
| Mirum Pharmaceuticals Inc | 32.67M |